Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Lucy Scientific Discovery Inc. LSDI NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score
21/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Lucy Scientific Discovery Inc. (LSDI) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.51. It has a SharesGrow Score of 20/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $7,048, +0%/yr average growth. Net income is $9M (loss), growing at -56.4%/yr. Net profit margin is -127532% (negative). Gross margin is 36.2% (+0 pp trend).

Balance sheet: total debt is $2M against $5M equity (Debt-to-Equity (D/E) ratio 0.38, conservative). Current ratio is 1.41 (adequate). Debt-to-assets is 20.4%. Total assets: $9M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 32/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

LSDI SharesGrow Score Overview

27/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 32/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LSDI

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
LSDI: +0%/yr revenue is, -56.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet LSDI: Debt-to-Equity (D/E) ratio 0.38 (conservative), Current ratio is 1.41 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
32/100
LSDI: Gross margin is 36.2% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 32/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
LSDI: Net profit margin is -127532%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.44-12.8
Volume306.79K
Avg Volume (30D)1.23M
Market Cap$906.91K
Beta (1Y)0.71
Share Statistics
EPS (TTM)-0.71
Shares Outstanding$12.7M
IPO Date2023-02-09
Employees2
CEORichard D. Nanula
Financial Highlights & Ratios
Revenue (TTM)$7.05K
Gross Profit$2.55K
EBITDA$-5.66M
Net Income$-8.99M
Operating Income$-5.84M
Total Cash$1.67M
Total Debt$1.79M
Net Debt$114.93K
Total Assets$8.78M
Price / Earnings (P/E)-0.7
Price / Sales (P/S)128.68
Analyst Forecast
Company Info
CountryCA
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA54960E2033

Price Chart

Track all markets on TradingView
LSDI
Lucy Scientific Discovery Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Drug Manufacturers - Specialty & Generic
0.44 52WK RANGE 12.80

People Also View

CTLT
CTLT
Catalent, Inc.
$63.48
+0.00%
 TLRY
TLRY
Tilray Brands, Inc.
$6.91
+2.83%
 ORGO
ORGO
Organogenesis Holdings Inc.
$2.51
+5.46%
 ALIM
ALIM
Alimera Sciences, Inc.
$5.54
-0.18%
 LFCR
LFCR
Lifecore Biomedical, Inc.
$5.20
+5.26%
 DERM
DERM
Journey Medical Corporation
$5.26
+1.15%
 CYTH
CYTH
Cyclo Therapeutics, Inc.
$0.72
+0.00%
 ADMP
ADMP
Adamis Pharmaceuticals Corporation
$0.78
+0.85%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message